


Investor Newsletter

Issue **01** 2018






FOXTROT™ NC



Foxtrot™ Pro



Firefighter™


Firefighter™, Foxtrot® Pro, and Foxtrot® NC Gain Regulatory Approval in India

On December 27, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") gained the approval from India's Central Drugs Standard Control Organization ("CDSCO") for its in-house developed Firefighter™ PTCA Balloon Catheter ("Firefighter™"), FOXTROT™ NC PTCA Balloon Catheter ("FOXTROT™ NC"), and FOXTROT™ PRO PTCA Balloon Catheter ("FOXTROT™ PRO"). They are the first batch of balloon catheters of MicroPort® that gained regulatory approval in India, marking the official entry of its new generation balloon catheter in the India market.

Previously, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") was approved to enter the India market, and has gained high recognition from physicians and patients with its excellent performance. As Firefighter™, Foxtrot Pro®, and Foxtrot® NC gained approval in India, they will further diversify MicroPort®'s cardiovascular product line in India and offer more comprehensive solutions for local patients. With their outstanding performance, they are expected to help MicroPort® further consolidate and expand its market share of cardiovascular products in India and other overseas markets.

Firehawk® Gains Regulatory Approval in Taiwan

MicroPort® received the regulatory approval from Taiwan Food and Drug Administration ("TFDA") for its in-house developed Firehawk®. It is the first drug-eluting stent in MicroPort® and the whole Chinese mainland that successfully gained the regulatory approval in Taiwan, marking a milestone in the development of MicroPort®'s cardiovascular business segment. With the increasing aging population, the incidence rate of coronary disease is constantly growing in Taiwan. According to statistics, there are around 30,000 PCI cases in the Taiwan market annually and the demand for coronary stent is rapidly increasing. With its outstanding performance, it is expected that Firehawk® will provide more ideal cardiovascular treatment for local patients and help enhance the communication between cardiologists from Taiwan and the mainland as well.



MicroPort® Endovascular Hercules™ Series Products Gain Regulatory Approval in Colombia

MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") obtained the regulatory approval from Colombia's health authority INVIMA for its in-house developed Hercules™-T Low Profile Stent-Graft ("HT-LP"), Hercules™ Bifurcated Stent-Graft System and Delivery System, and Hercules™ Balloon Dilation Catheter. This is the first time for MicroPort® Endovascular's products to gain regulatory approval in Colombia. Previously, the three products have received approval in Brazil, Argentina, Peru, Thailand, Indonesia, and the Philippines.


As the third largest country in Latin America, Colombia has a population of 50 million with a huge, growing market for cardiovascular interventional and endovascular products. In 2017, Firehawk® obtained the regulatory approval in Colombia. As HT-LP, Hercules™ Bifurcated Stent-Graft System and Delivery System, and Hercules™ Balloon Dilation Catheter gained the regulatory approval in Colombia, MicroPort® will further expand the Colombia market. With their outstanding performance, it is expected that they will provide better solutions for overseas patients and help MicroPort® Endovascular further enlarge its international market share, especially in Latin American countries.



Hercules™-T Low Profile Stent-Graft



Hercules™ Bifurcated Stent-Graft System



Hercules™ Balloon Dilation Catheter

MicroPort® Signs Strategic Agreement with **Neptunus Biotechnology**

MicroPort® reached a strategic agreement with Shenzhen Neptunus Biotechnology Co, Ltd. ("Neptunus Biotechnology"). Meanwhile, MicroPort® entered into a cooperation agreement with Neptunus Juying Medical Device Distribution Service Platform. MicroPort® and Neptunus Biotechnology reached the strategic agreement in order to cope with new medical device policies, such as Two Invoice System and Whole Process Traceability System. The two parties will share resources to explore innovative business modes. This partnership will bring together MicroPort®'s existing product lines and Neptunus Biotechnology's logistic platform and IT facilities in building up a professional nation-wide supply pipeline centered in cardiovascular interventional products to offer high-quality service to distributors, hospitals, and patients.



SuperPath™ Technique Helps 103-Year-Old Stand on His Feet the Same Day after Surgery

A 103-year-old patient successfully received SuperPath™ surgery in Zhengjiang First People's Hospital, which helped him to stand on his own feet the same day after the surgery. He is the oldest patient to be effectively treated by SuperPath™ surgery in China.

As the world's first total hip arthroplasty minimally invasive technique that facilitates a faster return to function for patients, SuperPath™ technique is a milestone in the development of hip replacement. It has been gained higher recognition in US and European countries, and was introduced to China in 2014 by Shanghai MicroPort Orthopedics Co., Ltd., a subsidiary of MicroPort®. Compared to traditional hip replacement technique, SuperPath™ causes incision as little as a 3-inch and ensures the maximum protection of soft tissue. Because of the preservation of external rotators and joint capsule, SuperPath™ technique reduces blood loss and tissue damage, leading to fewer post-operative restrictions, faster return to function, and improved satisfaction for patients. SuperPath™ technique not only offers patients with small incision, but also preserves the soft tissue to the largest extent which leads to added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. Patients can walk as early as four hours after surgery.



MicroPort® Gains its Fifth State Science and Technology Progress Award

The project of "Key Technology Development and Large-scale Industrialization of Aortic Stent Graft Products", jointly developed by MicroPort®, its subsidiary MicroPort® Endovascular, and Beijing Anzhen Hospital of Capital Medical University, won the second prize of State Science and Technology Progress Award. It is the fifth State Science and Technology Progress Award earned by MicroPort® and its subsidiaries, making MicroPort® the only medical company winning the national award for four consecutive years.

The project of "Key Technology Development and Large-scale Industrialization of Aortic Stent Graft Products" is the result of 15 years of innovation and hard work of MicroPort®. The project focused on studies of core material, product design, and clinical application of minimally invasive interventional treatment of aortic diseases. It successfully made breakthroughs in the production of key material, design rationale, and key manufacturing technique, and delivered a series of world-class domestically made aortic stent graft systems, including CRONUS™ Surgical Stent Graft System ("CRONUS™"), Hercules™-T Low Profile Stent-Graft ("HT-LP") and Delivery System, and Aegis™ Bifurcated Stent-Graft System ("Aegis™") and Delivery System, to effectively promote the development of diagnosis and treatment technology of aortic diseases as well as the industrial chain of minimally invasive interventional treatment of aortic diseases in China.

The project successfully breaks the US monopoly of the core material of aortic stent graft system. The products included in the project adopt advanced weaving technology, breaking through the obstacle in the production and application of ultra-thin vascular prosthesis graft material, making the production of domestically made aortic stent graft systems no longer restricted to overseas suppliers, and largely shortening the product development cycle. The project also makes China the second country after the US that masters the technology of producing vascular prosthesis graft material. The material it produces is of world-class quality, with its anti-fatigue property improved 50% and thickness reduced 30% compared to similar imports.





Brand

MicroPort® Awarded "Shanghai Top Brand"

MicroPort® was recently awarded "Shanghai Top Brand", according to a list released by Shanghai Top Brand Recommendation Committee, for its English and Chinese brand name "MicroPort®" and "微创®" (recommended product: Rapamycin-Eluting Coronary CoCr Stent System). MicroPort® has been awarded such honor for 12 consecutive years since 2005. The title will be valid till December 31, 2019. The title of "Shanghai Top Brand" signifies that the MicroPort® brand and its products are gaining higher social awareness, due to its industry-leading product quality and corporate governance. In the future, MicroPort® will continue to carry out the management credo of "Hands on Details, Eyes for Greatness" to offer cost-effective medical solutions to save or reshape lives or improve the quality of life for patients in China and worldwide.



MicroPort® Attends the CCC2018

From January 19 to January 21, MicroPort® attended the Ninth Clinical Cardiology Conference ("CCC2018") and the 15th Coronary Interventional Salon of China ("CISC2018") to display Firehawk® and other innovative products as well as hosted a case competition focused on the treatment of complex lesion and CTO re-infarction. During the meeting, experts spoke highly of its excellent crossability and compliance. The R&D staff also discussed with the two experts about the clinical needs of left auricle occlude and drug eluting balloon, and collected information regarding CTO technique strategies and complex, high-risk patients management, to lay a solid foundation for further optimization of product performance.



MicroPort® EP Attends 2018 Dunhuang Cardiovascular Disease Forum to Display Columbus™

From January 5 to January 6, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") attended the "Dunhuang Cardiovascular Disease Forum – the Application of 3D Navigation Technology in the Treatment of Complex Cardiac Arrhythmias" that was held in the First Hospital of Lanzhou University in Lanzhou of Gansu Province, and displayed its Columbus™ 3D EP Navigation System ("Columbus™"). Columbus™ is the only domestically made 3D EP navigation system with the CE certificate, which fills gaps in the field of domestically made EP devices and effectively lowers the medical cost for patients. As the only domestic company that provides a complete solution of cardiac EP treatment, MicroPort® EP will continue to strive for innovation and perfection to provide better arrhythmia solutions for patients and physicians.

Investor Newsletter

Issue **01** 2018



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com